Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AMN107: tightening the grip of imatinib.
O'Hare T, Walters DK, Deininger MW, Druker BJ. O'Hare T, et al. Among authors: druker bj. Cancer Cell. 2005 Feb;7(2):117-9. doi: 10.1016/j.ccr.2005.01.020. Cancer Cell. 2005. PMID: 15710324 Free article. Review.
Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes.
Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R, Druker BJ. Walters DK, et al. Among authors: druker bj. Leuk Res. 2006 Sep;30(9):1097-104. doi: 10.1016/j.leukres.2006.01.001. Epub 2006 Feb 7. Leuk Res. 2006. PMID: 16464493
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ. Walters DK, et al. Among authors: druker bj. Cancer Cell. 2006 Jul;10(1):65-75. doi: 10.1016/j.ccr.2006.06.002. Cancer Cell. 2006. PMID: 16843266 Free article.
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW. Griswold IJ, et al. Among authors: druker bj. Mol Cell Biol. 2006 Aug;26(16):6082-93. doi: 10.1128/MCB.02202-05. Mol Cell Biol. 2006. PMID: 16880519 Free PMC article.
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. DeAngelo DJ, et al. Among authors: druker bj. Blood. 2006 Dec 1;108(12):3674-81. doi: 10.1182/blood-2006-02-005702. Epub 2006 Aug 10. Blood. 2006. PMID: 16902153 Free PMC article. Clinical Trial.
440 results